943 related articles for article (PubMed ID: 30258937)
1. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Feng Y; Spezia M; Huang S; Yuan C; Zeng Z; Zhang L; Ji X; Liu W; Huang B; Luo W; Liu B; Lei Y; Du S; Vuppalapati A; Luu HH; Haydon RC; He TC; Ren G
Genes Dis; 2018 Jun; 5(2):77-106. PubMed ID: 30258937
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanism of Breast Cancer and Predisposition of Mouse Mammary Tumor Virus Propagation Cycle.
Ghosh A; Gopinath SCB
Curr Med Chem; 2024 May; ():. PubMed ID: 38721792
[TBL] [Abstract][Full Text] [Related]
3. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
4. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
[TBL] [Abstract][Full Text] [Related]
5. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
[TBL] [Abstract][Full Text] [Related]
6. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer.
Hu X; Zhang Q; Xing W; Wang W
Front Pharmacol; 2022; 13():814971. PubMed ID: 35814205
[No Abstract] [Full Text] [Related]
8. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling.
Molyneux G; Smalley MJ
J Mammary Gland Biol Neoplasia; 2011 Apr; 16(1):51-5. PubMed ID: 21336547
[TBL] [Abstract][Full Text] [Related]
9. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
10. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.
Saha T; Lukong KE
Front Oncol; 2022; 12():856974. PubMed ID: 35392236
[TBL] [Abstract][Full Text] [Related]
12. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?
Tan AR; Alexe G; Reiss M
Breast Cancer Res Treat; 2009 Jun; 115(3):453-95. PubMed ID: 18841463
[TBL] [Abstract][Full Text] [Related]
14. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
15. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
[TBL] [Abstract][Full Text] [Related]
16. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity in breast carcinoma cells with increased invasive capacities.
Negro G; Aschenbrenner B; Brezar SK; Cemazar M; Coer A; Gasljevic G; Savic D; Sorokin M; Buzdin A; Callari M; Kvitsaridze I; Jewett A; Vasileva-Slaveva M; Ganswindt U; Skvortsova I; Skvortsov S
Radiol Oncol; 2020 Feb; 54(1):103-118. PubMed ID: 32061169
[TBL] [Abstract][Full Text] [Related]
18. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
Larsen MJ; Thomassen M; Tan Q; Lænkholm AV; Bak M; Sørensen KP; Andersen MK; Kruse TA; Gerdes AM
BMC Med Genomics; 2014 Jan; 7():9. PubMed ID: 24479546
[TBL] [Abstract][Full Text] [Related]
19. CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression.
Zhang M; Zhang L; Geng A; Li X; Zhou Y; Xu L; Zeng YA; Li J; Cai C
Cell Rep; 2022 Sep; 40(11):111331. PubMed ID: 36103813
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
